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Oxidative phenotypeLoss of skeletal muscle oxidative fiber types and mitochondrial capacity is a hallmark of chronic obstructive
pulmonary disease and chronic heart failure. Based on in vivo human and animal studies, tissue hypoxia has
been hypothesized as determinant, but the direct effect of hypoxia on muscle oxidative phenotype remains to
be established. Hence, we determined the effect of hypoxia on in vitro cultured muscle cells, including gene
and protein expression levels of mitochondrial components, myosin isoforms (reflecting slow-oxidative versus
fast-glycolytic fibers), and the involvement of the regulatory PPAR/PGC-1α pathway. We found that hypoxia
inhibits the PPAR/PGC-1α pathway and the expression of mitochondrial components through HIF-1α. However,
in contrast to our hypothesis, hypoxia stimulated the expression of slow-oxidative type I myosin via HIF-1α.
Collectively, this study shows that hypoxia differentially regulates contractile and metabolic components of
muscle oxidative phenotype in a HIF-1α-dependent manner.
© 2014 Published by Elsevier Inc.1. Introduction
Hypoxia has been implicated in skeletal muscle metabolic impair-
ments in chronic diseases such as chronic obstructive pulmonary
disease (COPD) and chronic heart failure (CHF) [1–4]. Although it is gen-
erally known that hypoxia is involved in the stimulation of glycolyticme-
tabolism through among others the hypoxia-inducible factor 1 (HIF-1)
[5], a direct role for hypoxia in the downregulation of oxidative
metabolism is less firmly established. Skeletal muscle of patients with
COPD or CHF is characterized by an impaired oxidative phenotype,
including reduced oxidative enzyme activities and a shift from oxidative
to glycolytic fiber types [1,6]. Hypoxia has been suggested to be involved
in this downregulation of muscle oxidative phenotype [1]. However,
studies involving humans as well as experimental animal models result-
ed in inconsistent findings; i.e. loss of, unchanged or even improvedmus-
cle oxidative phenotype has been shown [7–17]. These inconsistencies
are inherent to the in vivo nature of these studies in which any direct ef-
fect of hypoxia probably was confounded by indirect effects, such as
hypoxia-induced changes in food intake, physical activity or circulating
hormone levels. Moreover, mountain expeditions were frequently seized
to study muscular adaptations to hypoxia in humans, thereby however
certainly introducing strenuous exercise as a confounding factor, as well31 87 7845882.
Slot),
vosse@mumc.nl (B.A.H. Vosse),
.gosker@maastrichtuniversity.nlas disturbance of the sleep cycle, cold temperatures and the anorexic ef-
fect of altitude [13,18,19].
In response to cellular hypoxia, cells are forced to limit oxygen
consumption and to shift from mitochondrial respiration to glycolysis
for ATP production [20]. Hypoxia-inducible factor (HIF) protein, the
master regulator of the hypoxic response, is stabilized under hypoxic
conditions anddirectly involved in theupregulation of several glycolytic
enzymes to stimulate glycolytic metabolism [21]. Also, overexpression
of HIF-1α has been linked to a fast muscle fiber type [22]. It is however
unclear whether hypoxia can reciprocally inhibit oxidative phenotype
in muscle, although it has been shown that HIF-1α knockout mice in-
deed demonstrate a modestly improved activity of oxidative enzymes
[23].
Master regulators of oxidative phenotype are the peroxisome
proliferator-activated receptors (PPARs) and specifically the PPARγ
coactivator-1 family (PGC-1s) [24,25]. PGC-1s coactivate not only
PPARs, but also estrogen-related receptors (ERRs) and nuclear
respiratory factors (NRFs), to stimulate mitochondrial biogenesis and
oxidative capacity [26,27]. Decreased expression levels of PPARs and
PGC-1α have indeed been shown in skeletal muscle of COPD patients
[28] and rats with CHF [29], suggesting potential involvement of these
factors in the loss of oxidative capacity.
In this study, we investigated the direct effect of hypoxia on
oxidative phenotype in an in vitro model of muscle fibers (myotubes)
and the role of HIF-1α herein. We hypothesized that hypoxia impairs
muscle oxidative phenotype in a HIF-1α-dependent manner by
downregulating the PPAR/PGC-1α pathway, either through direct
targeting of the PPARs or by influencing expression or activity of PPAR
co-regulators.
1838 I.G.M. Slot et al. / Cellular Signalling 26 (2014) 1837–18452. Materials and methods
2.1. Chemicals, reagents and materials
All reagents used were analytical grade. Tricine, glycine, sodium
chloride (NaCl), potassium chloride (KCl), disodium hydrogen phos-
phate (Na2HPO4), monopotassium phosphate (KH2PO4), magnesium
sulfate (MgSO4), magnesium carbonate ([MgCO3]4Mg[OH]2·5H2O)
and cobalt chloride (CoCl2) were obtained from Merck (Roden,
The Netherlands). Tris, methanol, ethylenediaminetetraacetic acid
(EDTA), sodium dodecyl sulfate (SDS), glycerol, nonidet P40, sodium
orthovanadate (Na3VO4), dithiothreitol (DTT), phenylmethylsulfonyl
fluoride (PMSF), leupeptin, aprotinin, bromophenol blue, coenzyme A,
dimethyl sulfoxide (DMSO), and bovine serum albumin (BSA) were
from Sigma (Zwijndrecht, The Netherlands). ATP was purchased from
Roche (Woerden, The Netherlands) and GW-501516 from Alexis Bio-
chemicals (Lausen, Switzerland).
Cell culture flasks and stripettes were from Corning Life Sciences
BV (Schiphol-Rijk, The Netherlands) and culture dishes from BD
Falcon (Breda, The Netherlands). Fetal bovine serum (FBS), penicillin/
streptomycin and Hank's Buffered Salt Solution (HBSS; calcium-,
magnesium- and phenol red-free) were from PAA Laboratories
(Pasching, Germany). Dulbecco's Modified Eagle's Medium (DMEM)
was purchased from Invitrogen (Breda, The Netherlands) and Matrigel
from BD Biosciences (San Jose, CA, USA). TNF-α was obtained from
Calbiochem (Nottingham, United Kingdom) and dissolved in 0.1% BSA.
Reporter Lysis 5× Buffer and beetle luciferin potassium salt for lucifer-
ase reporter assays were from Promega (Leiden, The Netherlands).
2.2. Cell culture
The in vitro model for assessing the effect of hypoxia on muscle
consisted of myotubes that were exposed for some hours up to sev-
eral days to hypoxic conditions. Murine skeletal muscle C2C12 cells
were obtained from the American Tissue Culture Collection (ATCC,
no. CRL-1772; Manassas, VA, USA). Myocytes were cultured in growth
mediumconsisting of low glucoseDMEM, 9% (v/v) FBS, 45 U/ml penicil-
lin and 45 μg/ml streptomycin in a 37 °C incubator with 5% CO2.
Cells were seeded on Matrigel-coated 35-mm dishes at a density
of 4 · 104 cells/cm2 and grown to ±80% confluency after which dif-
ferentiation was induced by two washes with HBSS and addition of
differentiation medium (DMEM, 1% [v/v] heat-inactivated FBS
[30 min at 56 °C], 50 U/ml penicillin and 50 μg/ml streptomycin).
After 5 days myotubes were fully differentiated and used for the actual
experiments. For hypoxic conditions,myotubeswere placed in a hypox-
ic incubator with 4% O2, 5% CO2 and 91% N2 for 24 h up to 3 days, de-
pending on the type of experiment.
2.3. Luciferase reporter assays
To assess the effect of hypoxia on the transcriptional activity of
HIF, PPAR and NF-κB transcription factors, C2C12 cells were stably
transfected with luciferase reporter plasmids sensitive to HIF (HIF
reporter), PPAR (PPAR reporter) or NF-κB (NF-κB reporter), respec-
tively. The HIF reporter expresses the luciferase gene controlled by
a promoter bearing five consecutive hypoxia-inducible factor (HIF)
responsive elements (HREs) from the human vascular endothelial
growth factor A (VEGFA) promoter (5HRE/hCMVmp-luc [30]) and
was kindly provided by Dr. Twan van den Beucken (Maastricht
University, The Netherlands). As a positive control, HIF-1α was
stabilized under normoxic conditions by adding CoCl2 to a final
concentration of 150 μM. The PPAR reporter promoter contains the
peroxisome proliferator-activated receptor (PPAR)-responsive ele-
ment from the human carnitine palmitoyltransferase 1B promoter
(MCPT.Luc.1025 [31]) and was a gift from Dr. Marc van Bilsen
(Maastricht University). The NF-κB reporter plasmid holds threerepeats of the human immunodeficiency virus type 1 (HIV-1) tan-
demNF-κB sites in front of a minimal thymidine kinase (TK) promot-
er (6 × κB-tk Luc [32]) and was kindly provided by Dr. Patrick
Baeuerle (Micromet, Germany). As a positive control, NF-κB tran-
scriptional activity was stimulated by adding TNF-α to selected
dishes at 10 ng/ml. BSA was added to dishes to a final concentration
of 0.005% as a vehicle control for the TNF-α treated dishes.
To assess treatment-associated expression of luciferase, myotubes
were harvested by washing twice with cold phosphate-buffered saline
(PBS; 137 mM NaCl, 2.7 mM KCl, 10.1 mM Na2HPO4, 1.8 mM KH2PO4,
pH 7.4) and lysis in Reporter Lysis 5× Buffer by scraping with a rubber
policeman and freezing at −80 °C. After thawing, insoluble material
was spun down in 2 min at 20000 ×g and the soluble fraction was
used for luciferase activity assay. Samples were analyzed on a single-
tube luminometer with injector (LB9507, Berthold Technologies, Bad
Wildbad, Germany) to add Luciferase Assay Reagent (20 mM Tricine,
1.07 mM [(MgCO3)4Mg(OH)2·5H2O], 2.67 mM MgSO4, 0.1 mM EDTA,
33.3 mM DTT, 270 μM coenzyme A, 470 μM beetle luciferin potassium
salt and 580 μM ATP, pH 7.8) to the sample. Luciferase activities were
expressed relative to protein concentration in the soluble fraction
as measured by Bio-Rad Protein Assay (Bio-Rad, Veenendaal, The
Netherlands) in a microtiter plate according to the manufacturer's
protocol.
2.4. RNA extraction and qRT-PCR analysis
RNA was extracted using the RNeasy Plus Mini Kit (Qiagen, Venlo,
The Netherlands) with gDNA eliminator spin columns to remove geno-
mic DNA according to the manufacturer's protocol. After elution, RNA
concentration was determined using a spectrophotometer (NanoDrop
ND-1000, Isogen Lifescience, IJsselstein, The Netherlands) and integrity
verified for a selection of samples by gel electrophoresis.
400 ng RNAwas reverse transcribed to cDNAwith amix of anchored
oligo(dT) and randomhexamer primers according to the supplier's pro-
tocol (Transcriptor First Strand cDNA Synthesis kit, Roche Diagnostics,
Woerden, The Netherlands). Quantitative reverse-transcription PCR
(qRT-PCR) primers were based on Ensembl [33] transcript sequences
and designed intron-spanning if possible. Primers were ordered from
Sigma Genosys (Zwijndrecht, The Netherlands) (Tables 1 and 2). For
relative quantification, standard curves were prepared from pooled
neat cDNA aliquots of all samples by five serial five-fold dilutions.
cDNA samples were diluted 1/50 and for both standards and samples,
5 μl diluted cDNA was loaded in a Hard-Shell Full-Height 96-Well
Semi-Skirted PCR Plate (Bio-Rad) covered with Microseal ‘B’ adhesive
seals (Bio-Rad). cDNA was amplified with SensiMix SYBR & Fluorescein
Kit (Quantace-Bioline, London, UK) supplementedwith 300 nMprimers
on a Bio-Rad MyiQ thermocycler (Bio-Rad). Two-step PCR was per-
formedwith the following cycling conditions: 10min at 95 °C, 40 cycles
of 10 s at 95 °C and 15 s at 60 °C and then 30 s at 95 °C and 30 s at 60 °C,
followed by a melting curve (heating from 60 °C to 95 °C with 10 s per
0.5 °C increase). Standard curves andmelt curves were analyzed to ver-
ify efficiency and specificity of amplification. Five reference genes
(Axin1, B2m, Canx, Ppia and Rplp0) were measured and stability of ex-
pressionwas assessed by visual inspection of expression differences be-
tween the study conditions and a stability assessment by geNorm [34].
Stable genes were included to calculate a normalization factor to nor-
malize expression levels of the other measured target genes.
2.5. Western blot analysis
Cells were washed twice with ice-cold PBS followed by 10 min
incubation in lysis buffer (20 mM Tris, 150 mM NaCl, 1% (v/v) nonidet
P40, 1 mM DTT, 1 mM Na3VO4, 1 mM PMSF, 10 μg/ml leupeptin, 1%
(v/v) aprotinin, pH 7.4) on ice. Cells were scraped with rubber police-
men and lysates were incubated for 30 min on a rotating wheel at
4 °C. Insoluble contents were precipitated during 30 min centrifugation
Table 1
qRT-PCR primer details for reference genes.






Axin1 Axin 1 ENSMUSG00000024182 AGTGGATCATTGAGGGAGAGA GCCCCAGGACGCTCGAT 124
B2m Beta-2-microglobulin ENSMUSG00000060802 CTTTCTGGTGCTTGTCTCACTGA GTATGTTCGGCTTCCCATTCTC 104
Canx Calnexin ENSMUSG00000020368 GCAGCGACCTATGATTGACAACC GCTCCAAACCAATAGCACTGAAAGG 170
Ppia Peptidyl-prolyl cis–trans isomerase
A; cyclophilin A
ENSMUSG00000071866 TTCCTCCTTTCACAGAATTATTCCA CCGCCAGTGCCATTATGG 75
Rplp0 Large ribosomal protein P0 ENSMUSG00000067274 GGACCCGAGAAGACCTCCTT GCACATCACTCAGAATTTCAATGG 85
1839I.G.M. Slot et al. / Cellular Signalling 26 (2014) 1837–1845at 20000 ×g at 4 °C. A small volume of soluble fraction was kept for
protein assay and the rest diluted in 4× sample buffer (0.25 M Tris,
8% (w/v) SDS, 40% glycerol, 0.4 M DTT, 0.02% bromophenol blue,
pH 6.8) and boiled for 5min at 95 °C. Per sample, 20 μg proteinwas sep-
arated on gel (4–12% Bis-Tris XT gel, Criterion, Bio-Rad) with XT MOPS
running buffer (Bio-Rad). Proteins were transferred to a 0.45 μm nitro-
cellulose membrane (Protran, Schleicher and Schuell, 's-Hertogenbosch,
The Netherlands) in transfer buffer (25 mM Tris, 192 mM glycine, 20%
(v/v) methanol) by electrophoresis for 3 h at 30 mA and 4 °C. After
transfer, membranes were blocked from nonspecific protein binding
with 5% non-fat dry milk (Campina, Eindhoven, The Netherlands) in
Tris-buffered saline (TBS; 25 mM Tris, 137 mM NaCl, 2.7 mM KCl,
pH 7.4)with 0.05% Tween 20 (TBST) in 1 h at room temperature, follow-
ed by incubation in primary antibody overnight at 4 °C (mouse anti-
myosin slow (M8421, Sigma), mouse anti-myosin fast (M4276,
Sigma), mouse anti-Total OXPHOS Rodent WB Antibody Cocktail
(MS604-300, MitoSciences, Eugene, OR, USA), rabbit anti-GAPDH
(#2118, Cell Signaling Technology, Beverly, MA, USA), or mouse anti-
α-tubulin (T6074, Sigma) diluted in 5% BSA (Sigma) in TBST). Mem-
branes were incubated in secondary antibody solutions (peroxidase-
labeled horse anti-mouse IgG [Vector Laboratories, Burlingame, CA,
USA] in 5% non-fat dry milk in TBST) during 3 h at room temperature
before incubation with enhanced chemiluminescence substrate
(Pierce SuperSignal West PICO Chemiluminescent Substrate; Thermo
Fisher Scientific, Breda, The Netherlands). Protein bands were detectedTable 2
qRT-PCR primer details for genes of interest.
Symbol Name Ensembl ID
Cox5a Cytochrome c oxidase subunit Va ENSMUSG00000000088
Cyc1 Cytochrome c-1 ENSMUSG00000022551
Esrra Estrogen-related receptor alpha ENSMUSG00000024955
Gabpa GA binding protein alpha;
nuclear respiratory factor 2 alpha
ENSMUSG00000008976
Hif-1a Hypoxia inducible factor 1 alpha ENSMUSG00000021109
Hk2 Hexokinase II ENSMUSG00000000628
Hmox1 Heme oxygenase 1 ENSMUSG00000005413
Myh1 Myosin heavy chain 1 (type IIx isoform) ENSMUSG00000056328
Myh2 Myosin heavy chain 2 (type IIa isoform) ENSMUSG00000033196
Myh4 Myosin heavy chain 4 (type IIb isoform) ENSMUSG00000057003
Myh7 Myosin heavy chain 7 (type I isoform) ENSMUSG00000053093
Ndufb5 NADH dehydrogenase (ubiquinone)
1 beta subcomplex 5
ENSMUSG00000027673
Nrf1 Nuclear respiratory factor 1 ENSMUSG00000058440
Ppara Peroxisome proliferator-activated receptor alpha ENSMUSG00000022383
Ppard Peroxisome proliferator-activated receptor delta ENSMUSG00000002250
Ppargc1a Peroxisome proliferator-activated receptor
gamma coactivator 1 alpha
ENSMUSG00000029167
Ppargc1b Peroxisome proliferator-activated receptor
gamma coactivator 1 beta
ENSMUSG00000033871
Sdhb Succinate dehydrogenase complex, subunit B ENSMUSG00000009863
Slc2a1 Glucose transporter (GLUT) 1 ENSMUSG00000028645
Tfam Mitochondrial transcription factor A ENSMUSG00000003923
Vegfa Vascular endothelial growth factor A ENSMUSG00000023951using Super RX films (Fujifilm, Düsseldorf, Germany) and scanned on a
GS-800 densitometer (Bio-Rad). Bands were quantified using Quantity
One software (v4.6.2, Bio-Rad), with GAPDH or α-tubulin as loading
control. Equal GAPDH or α-tubulin content in normoxic compared to
hypoxic samples was verified before correction of the other protein
targets.
2.6. Transient knockdown of HIF-1α gene expression
To study the role of HIF-1α in the response of oxidative capacity to
hypoxia, the gene expression of HIF-1α was knocked down by RNA in-
terference. Four-day old myotubes were transfected with Stealth RNAi
siRNA for HIF-1α (MSS205126, Invitrogen) or Stealth RNAi Negative
Control LO GC (Invitrogen) using Lipofectamine™ RNAiMAX
(Invitrogen) and returned to the normoxic incubator. The next day,
myotubes were exposed to hypoxia, or kept in normoxia. Medium
was replaced 48 h after transfection and cells were harvested 24 h later.
2.7. Transient overexpression of PPAR/PGC-1α protein
To disentangle through which molecule hypoxia exerts its effect on
PPAR transcriptional activity, myoblasts were transiently transfected
with expression plasmids encoding PPARα, PPARδ and PGC-1α protein,
which were kindly provided by Dr. Marc van Bilsen (Maastricht



























1840 I.G.M. Slot et al. / Cellular Signalling 26 (2014) 1837–1845expression plasmids has previously been shown in C2C12 myoblasts
[35]. Myoblasts were plated at a density of 30% and allowed to attach
overnight. The next day, the cells were transfected with plasmids
encoding murine PPARα (mPPARα), PGC-1α (mPGC1α) or rat PPARδ
(rPPARδ) or empty vector (pcDNA3.1+, Invitrogen) combined with a
vector expressing β-gal using PfU Nanofectin (PAA Laboratories). For
luciferase assays, the PPAR reporter plasmid was cotransfected. After a
two-hour incubation period, growth medium was replaced and dishes
were replaced to the hypoxic incubator or kept in normoxia. Cells
were harvested 24 h later. Luciferase activities were corrected for β-
gal activity to control for differences in transfection efficiencies.
2.8. Statistical analyses
Data were analyzed using IBM SPSS Statistics 21.0 (IBM Corp.,
Armonk, NY). Differences between samples exposed to hypoxia or CoCl2
and those exposed to normoxia were tested using the Mann–Whitney
test. Data are presented by mean + SD. A two-tailed p-value b 0.05
was considered statistically significant.
3. Results
3.1. Hypoxia impairs muscle oxidative capacity and the regulatory PPAR/
PGC-1α pathway
To study the effect of hypoxia on the markers of oxidative capacity,
myotubeswere exposed to hypoxia (4% O2) for three days. This resulted
in significantly decreased protein content of the oxidative phosphoryla-




































































































Fig. 1. Three days of hypoxia (4% O2) attenuates content and activity of several components a
phosphorylation (OXPHOS) complexes; B, gene expression levels of nuclear-encoded OXPHOS
of several regulators ofmitochondrial biogenesis and oxidative capacity, andD, PPAR transcripti
a hypoxiamimetic. Mean+ SD; expression levels were normalized with geNorm to RPLP0, B2M
IV; HKII, hexokinase-II; PPAR, peroxisome proliferator-activated receptor; PGC-1, PPAR gamma
α; NRF, nuclear respiratory factor. Experiments were performed in triplicate; *p b 0.05 comparprotein content was associated with lower gene expression levels of
OXPHOS subunits from complexes I to IV (Fig. 1B). At the same time,
gene expression of the glycolytic enzyme hexokinase-II was significant-
ly increased by hypoxia.
To investigate how regulators of mitochondrial biogenesis and
oxidative phenotype are affected by hypoxia, we measured the gene
expression levels of PPARα, PPARδ, PGC-1α, PGC-1β, Tfam, ERRα,
NRF-1 and NRF-2α. In response to hypoxia, the gene expression levels
of PPARα, PPARδ, PGC-1α, PGC-1β and ERRαweremarkedly decreased.
Levels of NRF-1 and NRF-2α were increased, whereas Tfam expression
levels were unchanged (Fig. 1C). It is worthmentioning that the expres-
sion of Tfamwas significantly decreased after 24 h exposure to hypoxia,
indicating that hypoxia reduced Tfam gene expression in a more tran-
sient fashion. As a functional signaling outcome measure, we assessed
PPAR transcriptional activity using the PPAR luciferase reporter cell
line and found it to be substantially decreased by hypoxia (Fig. 1D).
Hypoxia-induced increased PPARγ expression (data not shown)
suggests that the reduced PPAR transcriptional activity probably reflects
decreased PPARα or PPARδ activity.3.2. Hypoxia shifts muscle towards oxidative fiber-type I profile
To assess whether exposure to hypoxia induces a shift from oxida-
tive towards a more glycolytic fiber-type profile, we determined the
protein content and mRNA levels of the respective myosin heavy
chain (MyHC) isoforms in myotubes exposed to 4% oxygen for three
days. Protein content of the slow oxidative type I MyHC isoform was
markedly increased, while content of fast isoforms was reduced under


















































nd regulators of oxidative capacity. A, protein content of labile subunits of the oxidative
subunits of complexes I–IV and the glycolytic gene hexokinase-II; C, gene expression levels
onal activity by luciferase reporter assay. CoCl2 was added to additional normoxic dishes as
, PPIA and Axin1; Ndufb5, complex I; Sdhb, complex II; Cyc1, complex III; Cox5a, complex
coactivator 1; Tfam, mitochondrial transcription factor A; ERRα, estrogen-related receptor



































































Fig. 2.Hypoxia (4%O2) exposure for three days promotes expression of oxidativemyosin heavy chain (MyHC) isoforms inmyotubes. A, protein content of slow type I and fast type IIMyHC
isoforms and B, gene expression of MyHC isoforms. Mean + SD. Experiments were performed in triplicate; *p b 0.05 compared to normoxic control.
1841I.G.M. Slot et al. / Cellular Signalling 26 (2014) 1837–1845IIa MyHC were significantly increased, which was associated with a
reduction of MyHC type IIx and IIb mRNA levels (Fig. 2B).
3.3. Hypoxia induces HIF-1α transcriptional activity and stimulates
glycolytic metabolism in muscle
HIF transcriptional activity was measured in C2C12 cells that were
transfected with a plasmid carrying a luciferase gene under control of
HIF-responsive elements. Myoblasts transiently transfected with the
HIF reporter plasmid were exposed to 1%, 2%, 4% and 21% oxygen for
24 h. HIF luciferase reporter activity was strongly induced by lower









































































































Fig. 3. Exposure of myotubes to 4% oxygen stimulates HIF transcriptional activity, which can
luciferase reporter in myotubes exposed to several oxygen concentrations for one day; B, exp
HIF-1α expression after knockdown with HIF-1α siRNA in myotubes exposed to 4% O2 for th
with sham siRNA (sham) or HIF-1α siRNA (siHIF1α) and exposure to hypoxia (4% O2) or CoCl2
transporter 1; HO-1, heme oxygenase 1. Experiments were performed in triplicate; *p b 0.05 cevident. This oxygen level also has negligible effects on myotube
morphology and viability, indicating that this condition was most suit-
able for our experiments. To validate whether the hypoxic response
was physiologically intact, we determined the mRNA expression levels
of HIF-regulated genes in myotubes after three days of 4% oxygen
exposure. Levels of VEGF-A, GLUT1 and HO1 were significantly
increased in the hypoxic myotubes (Fig. 3B).
In addition to HIF-1α, two other HIFα isoforms, HIF-2α and HIF-3α,
have been described to mediate the hypoxic response. To confirm that
the HIF luciferase reporter mainly reflects HIF-1α transcriptional
activity, myotubes stably carrying the HIF luciferase reporter were
















































be inhibited by knockdown of HIF-1α gene expression. A, dose-dependency of the HIF
ression levels of HIF-1α-regulated genes in myotubes exposed to 4% O2 for three days; C,
ree days, and D, HIF transcriptional activity by luciferase reporter assay after treatment
for three days. Mean + SD; VEGF-A, vascular endothelial growth factor A; GLUT1, glucose
ompared to normoxic control or for the comparison indicated by the horizontal line.
1842 I.G.M. Slot et al. / Cellular Signalling 26 (2014) 1837–1845siRNA reduced the expression of the HIF-1α gene by 60–80% (Fig. 3C)
and more importantly, it completely abrogated the hypoxia-induced
increase of HIF luciferase reporter activity (Fig. 3D).3.4. Differential regulation of oxidative phenotype components is HIF-
1α-dependent
To assess the role of HIF-1α in the hypoxia-induced changes of mus-
cle oxidative phenotype, levels of markers of oxidative phenotype were
determined inmyotubes transiently transfectedwith theHIF-1α siRNA.
Knockdown of HIF-1α gene expression resulted in significant preserva-
tion of the protein content of the OXPHOS complex V subunit (Fig. 4A).
A similar but less pronounced effect was observed for OXPHOS genes
(data not shown), which corroborates that impairment of oxidative
phenotype occurs at the transcriptional level. Gene expression levels
of the transcription factors PPARα, PPARδ, and ERRα and their
coregulators PGC-1α and PGC-1βwere significantly reduced by hypox-
ia, however HIF-1α knockdown could only restore levels of PPARδ and
PGC-1α (Fig. 4B). Moreover, HIF-1α knockdown in hypoxia restored
PPAR transcriptional activity to normoxic levels (Fig. 4C). Together,
these data suggest that PPARδ or PGC-1α could be the mediator in
hypoxia-induced impairment of PPAR transcriptional activity.
Transient knockdown of HIF-1α expression resulted in attenuation
or even abrogation of hypoxia-stimulatedMyHC type I gene expression,








































































































































Fig. 4. HIF-1α knockdown results in sparing of oxidative capacity and blunted stimulation o
Myotubes were treated with sham siRNA (sham) or HIF-1α siRNA (siHIF1α), followed by m
alpha; B, geneexpression levels of several regulators ofmitochondrial biogenesis and oxidative c
levels of myosin heavy chain isoforms. Mean+ SD. Experiments were performed in triplicate;
line.3.5. Hypoxia-associated attenuation of PPAR transcriptional activity is
mediated through PGC-1α
To assess whether synthetic stimulation could abolish the effect
of hypoxia on PPAR transcriptional activity and identify PPARδ or
PGC-1α as the key factor, we investigated the influence of ligand-
dependent PPARδ activation and PPARδ/PGC-1α overexpression on
PPAR transcriptional activity under hypoxic conditions. PPAR lucifer-
ase reporter activity was reduced by hypoxia to a similar extent in
the absence and presence of GW501516, a specific PPARδ ligand
(Fig. 5A). However, by adding the PPARδ ligand PPAR transcriptional
activity in hypoxia could be normalized to levels similar to basal
PPAR transcriptional activity in normoxia.
Because myotubes are refractive to lipid-based transfection with
plasmids, undifferentiated myoblasts were transfected with the PPAR
luciferase reporter plasmid in combination with overexpression plas-
mids encoding either PPARδ, PPARα or PGC-1α. In myoblasts, PPAR
transcriptional activity was markedly reduced after 2 days of exposure
to hypoxia. Overexpression of PGC-1α radically increased PPAR tran-
scriptional activity 14-fold and this was not attenuated by hypoxia
(Fig. 5B). Overexpression of PPARδ resulted in amodest 4-fold induction
of PPAR transcriptional activity, but this effect was reduced by 25%
under hypoxic conditions. PPARα overexpression stimulated PPAR
transcriptional activity 17-fold, with a hypoxia-associated reduction of
this effect by 18%. Overexpression of PGC-1α did notmodify the expres-
sion levels of PPARα and PPARδ (Fig. 5C). Together with the reduced
sensitivity of the PPAR luciferase reporter to hypoxia in the presenceNormoxia
Hypoxia
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Fig. 5.Attenuation of PPAR transcriptional activity by hypoxia ismediated through suppression of PGC-1α expression. A, PPAR transcriptional activity inmyotubes stimulated for two days
with PPARδ agonist GW501516 (100 μM) or vehicle control (DMSO) during exposure to hypoxia; B, PPAR transcriptional activity inmyoblasts transiently transfectedwith overexpression
plasmids for murine PGC-1α (mPGC1α), PPARα (mPPARα) and rat PPARδ (rPPARδ) or empty vector (EV) after two days in normoxia or hypoxia. Activity is normalized to corresponding
normoxic conditions, and C, gene expression of PGC-1α, PPARα and PPARδ in myoblasts in the presence (mPGC1α) or absence (EV) of mPGC1α overexpression for two days. Expression
levels are normalized to respective EV controls. Experiments were performed in triplicate; *p b 0.05 compared to normoxic control or for the comparison indicated by the horizontal line.
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of hypoxia-associated attenuation of PPAR transcriptional activity and
muscle oxidative phenotype.
4. Discussion
In this studywe showed that hypoxia differentially regulatesmuscle
oxidative phenotype by directly downregulating oxidative capacity
through HIF-1α and PGC-1α and simultaneously stimulating oxidative
myosin heavy chain type I levels, also in a HIF-1α-dependent manner.
This suggests a segregation of the regulation of oxidative metabolism
and structural muscle proteins under hypoxic conditions.
HIF-1 activity is progressively stimulated by decreasing oxygen con-
centrations and was found to be an essential mediator of oxygen ho-
meostasis [36]. It has been shown that HIF-1α stimulates muscle
glycolytic phenotype [22] and HIF-1α knockout modestly improves
muscle oxidative phenotype [23]. However, these experiments were
performed in vivo and do not provide insight into the direct regulation
of muscle oxidative phenotype by HIF-1α. Therefore, we assessed the
role of HIF-1α in downregulation of muscle oxidative phenotype by
hypoxia. Indeed, we found significant stimulation of HIF transcriptional
activity in our model of hypoxia-exposedmyotubes. Our group recently
showed that activation of NF-κB by TNF-α impairs muscle oxidative
phenotype [35]. However, using the same NF-κB responsive luciferase
reporter construct we did not find increased activation of NF-κB by
hypoxia in C2C12 myotubes (data not shown). Further experiments
were therefore focused on modulation of HIF-1α.
PPARα, PPARδ, PGC-1α, PGC-1β and ERRα are important regulators
of oxidative capacity. Hypoxia generally reduced the gene expression
levels of all these markers. In addition, hypoxia markedly decreasedPPAR transcriptional activity. The PPAR reporter we used is responsive
to agonists for PPARα, PPARδ and PPARγ [37] and might thus be indi-
rectly affected by PGC-1α and PGC-1β via coactivation of these PPARs
[38]. Restoration of both PPAR transcriptional activity and gene expres-
sion levels of PPARδ and PGC-1α by HIF-1α knockdown suggests that
HIF-1α mediates the reduced PPAR transcriptional activity via either
PPARδ or PGC-1α. However, only overexpression of PGC-1α could pre-
vent hypoxia-associated depression of PPAR transcriptional activity
with no associated changes in PPARδ gene expression. It should be
noted that the overexpression studies were performed in myoblasts
rather than in myotubes, because of the technical limitation of myo-
tubes to be transfected with expression plasmids using lipid-based
techniques. However, also in untransfected myoblasts PGC-1α expres-
sion was reduced by hypoxia (data not shown).
A central role for PGC-1α in hypoxia-induced impairment of
oxidative capacity is further supported by the observation that HIF-1α
knockdown could successfully restore OXPHOS subunit V content and
OXPHOS gene expression. Regulation of OXPHOS expression levels is
mediated largely through PGC-1α [26] and whole-body PGC-1α knock-
out experiments in mice have shown that skeletal muscle expression of
OXPHOS genes is markedly blunted in the absence of PGC-1α [39].
A potential mechanism by which PGC-1α expression is negatively
modulated by hypoxia is via histone deacetylases (HDACs). Ramjiawan
et al. showed in hypoxic cardiomyocytes that histone 3 lysine 9 (H3K9)
acetylation was significantly reduced in the PGC-1α promoter region,
which resulted in reduced PGC-1α expression [40]. Blocking HDAC ac-
tivity abolished this hypoxia-induced loss of PGC-1α. Seo et al. showed
that HDAC4, -5 and -7 promote HIF-1α transactivation under hypoxic
conditions [41], whereas HDAC inhibitors inhibit HIF-1α activity [42].
We previously showed that skeletal muscle of patients with COPD, a
1844 I.G.M. Slot et al. / Cellular Signalling 26 (2014) 1837–1845disease associated with hypoxia, is characterized by a decreased gene
expression of PGC-1α and OXPHOS protein content [43], which is in
line with the results from the current study. Interestingly, in a different
study, HDAC4 protein contentwas shown to be increased in the quadri-
ceps muscle of patients with COPD compared to healthy controls [44].
Moreover, a systems biology approach comparing muscle biopsies
from patients with COPD and muscle tissue from mice exposed to
chronic hypoxia, identified hypoxia as a key factor in themuscle abnor-
malities in COPD, associated with increased HDAC expression [3].
It is of interest that supplementation of the muscle cells under
hypoxia with the selective PPARδ agonist GW501516 restored PPAR
transcriptional activity to normoxic levels. Although decreased
PGC-1α turned out to be most important for attenuation of PPAR
transcriptional activity under hypoxic conditions, PPARδ seems a
promising target for therapeutic intervention.
In contrast to what we expected, hypoxia induced rather than
inhibited the expression of the oxidative myosin heavy chain (MyHC)
type I gene and protein. Moreover, HIF-1α knockdown experiments
showed that MyHC type I induction was HIF-1α-dependent, unlike
the changes in gene expression levels of the other MyHC genes.
A role for PGC-1α in the hypoxia-associated increase of MyHC type I
expression is unlikely, because muscle-specific PGC-1α knockout mice
present with a fiber-type shift towards glycolytic rather than oxidative
fibers [45]. Moreover, transgenic mice that overexpress PGC-1α in the
muscle are characterized by an increased proportion of type Ifibers [46].
Interestingly, in cardiomyocytes a similar response of MyHC type
I (also known as β-myosin in the heart) to hypoxia was observed
[47]. To our knowledge, only one paper reports on myosin heavy
chain composition in C2C12 cells in relation to HIF-1α, showing
that HIF-1α overexpression stimulated the expression of MyHC IIb
and reduced MyHC I [22], although increased HIF-1α transcriptional
activity was not confirmed in this study. However, these cells were
still in a differentiating phase, whereas our C2C12 cells were fully
differentiated when exposed to hypoxia. Ishihara et al. showed that
the effect of hypoxia on fiber-type composition was indeed depen-
dent on the developmental stage of the rats exposed to hypoxia
[48]. Nevertheless, the hypoxia-associated increase of oxidative
MyHC isoforms that we found seems counterintuitive, because the
type I fibers rely primarily on oxidative energy metabolism for mus-
cle contraction. Possibly, the absence of contraction and
extramuscular factors such as nerve stimulation or hormones, results
in uncoupling of the regulation of MyHC profile and oxidative
capacity.4. Conclusions
Our results indicate that hypoxia could explain the loss of oxida-
tive capacity as observed in the muscles of for example patients with
COPD or CHF. However, the frequently co-occurring I-to-II fiber-type
shift is possibly caused or overruled by factors other than direct
hypoxia.
Our data furthermore suggests that the PPAR/PGC-1α pathway
would be an interesting target for pharmacological modulation to
treat disease-related loss of oxidative capacity. An intervention
study by Broekhuizen et al. indeed showed a significant improve-
ment of exercise capacity in COPD patients who received nutritional
supplementation with PPAR-activating poly-unsaturated fatty acids
(PUFAs) in addition to the effect of exercise training [49]. Although
no informationwas available on changes in skeletal muscle oxidative
capacity, it can be speculated that the PUFA-induced improvement in
exercise capacity was mediated by an improved muscle oxidative ca-
pacity. Further studies should focus on the effect of PUFA supple-
mentation on muscle oxidative capacity under hypoxic conditions
to explore PUFA supplementation as a therapy for hypoxia-
associated loss of muscle oxidative phenotype.Author contributions
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